心律失常与起搏领域临床研究2023年度进展

Progress of clinical research in arrhythmias and pacing 2023

回顾2023年心律失常领域重要临床试验,涉及心房颤动(房颤)、起搏等方面。CIRDADOSE研究及EARLY-AF研究均肯定冷冻球囊消融治疗房颤疗效,减慢房颤进展。MANIFEST-PF研究回顾房颤脉冲场消融的成功率及安全性,在ADVENT研究中再次证实其安全性和有效性不劣于传统热消融。在左束支区域起搏(LBBAP)研究中,与双心室起搏(BVP)相比,LBBAP降低持续性室性心动过速(VT)/心室颤动(VF)和新发房颤发生率。对于起搏比例高且射血分数降低的起搏器或植入式心律转复除颤器(ICD)患者,BUDAPEST CRT升级研究肯定了其升级到心脏再同步除颤器(CRT-D)的明确获益。DANPACEⅡ研究显示窦房结功能障碍患者的心房起搏最小化并不能降低房颤的发生率。IDE研究显示Aveir DR双腔无导线起搏器术后3个月安全性良好,可提供可靠的心房起搏和房室同步。iSUSI研究是对皮下植入式心律转复除颤器的注册研究,发现心力衰竭和非心力衰竭患者不恰当和恰当电击率相似。

Reviewing important clinical trials in the field of arrhythmia in 2023,involving atrial fibrillation,pacing,and other aspects.Both the CIRDA-DOSE study and the EARLY-AF study affirmed the efficacy of cryoballoon ablation in treating atrial fibrillation,alter its progression to persistent atrial fibrillation.The MANIFEST-PF study examined the success rate and safety of pulse field ablation in atrial fibrillation,and the ADVENT study also confirmed its safety and eff ectiveness not inferior to conventional thermal ablation.In the LBBAP study,LBBAP reduced the occurrence of sustained VT/VF and new-onset atrial fibrillation compared to BVP.For patients with a high right ventricular pacing burden and reduced ejection fraction in pacemakers or ICDs,the BUDAPEST CRT upgrade study affirmed the benefits of upgrading to CRT-D.The DANPACEⅡ study showed that minimizing atrial pacing in patients with sinus node dysfunction does not reduce the incidence of atrial fibrillation.The IDE study demonstrated the safety of Aveir DR dual-chamber leadless pacemaker at 3 months post-operation,providing reliable atrial pacing and atrioventricular synchrony.The iSUSI study is a registry study of subcutaneous implantable cardioverter-defibrillators,finding similar inappropriate and appropriate shock rates in patients with and without heart failure.